Rx Product Updates (December 2016)

Contemporary ClinicDecember 2016
Volume 2
Issue 6

Read about the new Rx products featured in December 2016.

Marketed by:Napo Pharmaceuticals

Indication:Mytesi (crofelemer) has been launched as the only FDA-approved treatment for the relief of non-infectious diarrhea in patients with HIV.

Dosage Form:Tablets: 125 mg

For More Information:napopharma.com


Marketed by:Validus Pharmaceuticals LLC

Indication:The FDA has approved Equetro (carbamazepine) for the treatment of pain associated with trigeminal neuralgia and as an antiepileptic drug for the treatment of partial seizures with complex symptomatology, generalized tonic-clonic seizures, and mixed seizures.

Dosage Form:Extended-release capsules: 100, 200, and 300 mg

For More Information:equetro.com


Marketed by:Genentech

Indication:The FDA has approved Tecentriq (atezolizumab) as the first, and only, anti-PDL1 cancer immunotherapy for metastatic non—small cell lung cancer.

Dosage Form:Injection: 1200 mg/20 mL (60 mg/mL) solution in a single-dose vial

For More Information:gene.com

Related Content
© 2024 MJH Life Sciences

All rights reserved.